"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype."

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hospital-acquired Pneumonia
Interventions
DRUG

Baricitinib 4 MG

Reference drug

Trial Locations (29)

Unknown

St-Luc Clinics, Brussels

Ghent University Hospital, Ghent

Groupe Jolimont, Haine-Saint-Paul

Clinique Saint-Pierre, Ottignies

University Hospital of UCL Namur, Yvoir

CHU Angers, Angers

CHU de Brest, Brest

CHU de Caen, Caen

CHU Clermont-Ferrand, Clermont-Ferrand

CHU de Clermont-Ferrand, Clermont-Ferrand

CHU de Clermont-Ferrand, Clermont-Ferrand

CH La Roche sur Yon, La Roche-sur-Yon

CHU de Limoges, Limoges

CHU de Marseille, Marseille

CHU de Nancy, Nancy

CHU de Nantes, Nantes

CHU de Nantes, Nantes

CHU de Nantes, Nantes

CHU de Nantes, Nantes

CHU de Beaujon, Paris

CHU la Pitié-Salpétrière, Paris

CHU Pitié-Salpétrière, Paris

CHU de Poitiers, Poitiers

CHU de Rennes, Rennes

CHU de Rennes, Rennes

University Medical Center Utrecht, Utrecht

Hospital Clinic, Barcelona

Hospital del Mar, Barcelona

Hospital Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT05914584 - "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype." | Biotech Hunter | Biotech Hunter